287 related articles for article (PubMed ID: 28988441)
1. A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor.
Estes C; Sadoughi B; Coleman R; Sarva H; Mauer E; Sulica L
Laryngoscope; 2018 Feb; 128(2):437-446. PubMed ID: 28988441
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of propranolol and botulinum for the treatment of essential voice tremor.
Justicz N; Hapner ER; Josephs JS; Boone BC; Jinnah HA; Johns MM
Laryngoscope; 2016 Jan; 126(1):113-7. PubMed ID: 26198384
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Patients with Vocal Fold Atrophy and Comorbid Essential Voice Tremor: Long-Term Injection Augmentation Outcomes After Successful Diagnostic Vocal Fold Injection Augmentation.
Van Doren M; Faudoa E; Carroll TL
J Voice; 2020 May; 34(3):471-476. PubMed ID: 30503608
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of essential voice tremor: a study of 34 cases.
Sulica L; Louis ED
Laryngoscope; 2010 Mar; 120(3):516-28. PubMed ID: 20066728
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of the vocal tremor scoring system.
Bové M; Daamen N; Rosen C; Wang CC; Sulica L; Gartner-Schmidt J
Laryngoscope; 2006 Sep; 116(9):1662-7. PubMed ID: 16955000
[TBL] [Abstract][Full Text] [Related]
6. A new paradigm for the management of essential vocal tremor with botulinum toxin.
Gurey LE; Sinclair CF; Blitzer A
Laryngoscope; 2013 Oct; 123(10):2497-501. PubMed ID: 23553653
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
8. Combined modality treatment of adductor spasmodic dysphonia.
Silverman EP; Garvan C; Shrivastav R; Sapienza CM
J Voice; 2012 Jan; 26(1):77-86. PubMed ID: 21292439
[TBL] [Abstract][Full Text] [Related]
9. Laryngeal Botulinum Toxin Injection for Vocal Tremor: Utility of Concurrent Strap Muscle Injection.
Nelson RC; Silva Merea V; Tierney WS; Milstein C; Benninger MS; Bryson PC
Laryngoscope; 2019 Jun; 129(6):1433-1437. PubMed ID: 30588631
[TBL] [Abstract][Full Text] [Related]
10. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A for treating voice tremor.
Adler CH; Bansberg SF; Hentz JG; Ramig LO; Buder EH; Witt K; Edwards BW; Krein-Jones K; Caviness JN
Arch Neurol; 2004 Sep; 61(9):1416-20. PubMed ID: 15364688
[TBL] [Abstract][Full Text] [Related]
12. The treatment of essential voice tremor with botulinum toxin A: a longitudinal case report.
Warrick P; Dromey C; Irish J; Durkin L
J Voice; 2000 Sep; 14(3):410-21. PubMed ID: 11021508
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Patients Receiving Short-Interval Botulinum Toxin Chemodenervation Treatment for Laryngeal Dystonia and Essential Tremor of the Vocal Tract.
Lagos-Villaseca A; Bhatt NK; Abdolhosseini P; Quinonez L; Paoletti MF; Gochman G; Johns MM; Rosen CA; Kao TC; Meyer TK
JAMA Otolaryngol Head Neck Surg; 2023 Jul; 149(7):615-620. PubMed ID: 37227721
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection.
Warrick P; Dromey C; Irish JC; Durkin L; Pakiam A; Lang A
Laryngoscope; 2000 Aug; 110(8):1366-74. PubMed ID: 10942143
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
Sulica L; Blitzer A; Brin MF; Stewart CF
Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
[TBL] [Abstract][Full Text] [Related]
16. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
Meyer TK; Hu A; Hillel AD
Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
[TBL] [Abstract][Full Text] [Related]
17. Validation of the OMNI vocal effort scale in the treatment of adductor spasmodic dysphonia.
Shoffel-Havakuk H; Marks KL; Morton M; Johns MM; Hapner ER
Laryngoscope; 2019 Feb; 129(2):448-453. PubMed ID: 30315575
[TBL] [Abstract][Full Text] [Related]
18. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of Parkinson's-related dysphonia.
Sewall GK; Jiang J; Ford CN
Laryngoscope; 2006 Oct; 116(10):1740-4. PubMed ID: 17003722
[TBL] [Abstract][Full Text] [Related]
20. Injection laryngoplasty as adjunct treatment method for muscle tension dysphonia: Preliminary findings.
Novakovic D; Nguyen DD; Chacon A; Madill C
Laryngoscope; 2020 Apr; 130(4):980-985. PubMed ID: 31361337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
